JP2025169389A5 - - Google Patents
Info
- Publication number
- JP2025169389A5 JP2025169389A5 JP2025136675A JP2025136675A JP2025169389A5 JP 2025169389 A5 JP2025169389 A5 JP 2025169389A5 JP 2025136675 A JP2025136675 A JP 2025136675A JP 2025136675 A JP2025136675 A JP 2025136675A JP 2025169389 A5 JP2025169389 A5 JP 2025169389A5
- Authority
- JP
- Japan
- Prior art keywords
- here
- dose
- formulation
- administered
- eye disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161432245P | 2011-01-13 | 2011-01-13 | |
| US61/432,245 | 2011-01-13 | ||
| US201161434836P | 2011-01-21 | 2011-01-21 | |
| US61/434,836 | 2011-01-21 | ||
| US201161561957P | 2011-11-21 | 2011-11-21 | |
| US61/561,957 | 2011-11-21 | ||
| JP2019104939A JP2019167366A (ja) | 2011-01-13 | 2019-06-05 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2021146749A JP2021193115A (ja) | 2011-01-13 | 2021-09-09 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023174006A JP7733706B2 (ja) | 2011-01-13 | 2023-10-06 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174006A Division JP7733706B2 (ja) | 2011-01-13 | 2023-10-06 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025169389A JP2025169389A (ja) | 2025-11-12 |
| JP2025169389A5 true JP2025169389A5 (cg-RX-API-DMAC10.html) | 2026-03-25 |
Family
ID=45507924
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549502A Withdrawn JP2014503555A (ja) | 2011-01-13 | 2012-01-11 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2016202169A Pending JP2017061467A (ja) | 2011-01-13 | 2016-10-14 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2019104939A Pending JP2019167366A (ja) | 2011-01-13 | 2019-06-05 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2021146749A Pending JP2021193115A (ja) | 2011-01-13 | 2021-09-09 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023174006A Active JP7733706B2 (ja) | 2011-01-13 | 2023-10-06 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025136675A Pending JP2025169389A (ja) | 2011-01-13 | 2025-08-20 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549502A Withdrawn JP2014503555A (ja) | 2011-01-13 | 2012-01-11 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2016202169A Pending JP2017061467A (ja) | 2011-01-13 | 2016-10-14 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2019104939A Pending JP2019167366A (ja) | 2011-01-13 | 2019-06-05 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2021146749A Pending JP2021193115A (ja) | 2011-01-13 | 2021-09-09 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023174006A Active JP7733706B2 (ja) | 2011-01-13 | 2023-10-06 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (14) | US9254338B2 (cg-RX-API-DMAC10.html) |
| EP (4) | EP3222285A1 (cg-RX-API-DMAC10.html) |
| JP (6) | JP2014503555A (cg-RX-API-DMAC10.html) |
| KR (8) | KR20180023015A (cg-RX-API-DMAC10.html) |
| CN (1) | CN103533950A (cg-RX-API-DMAC10.html) |
| AU (5) | AU2012205599B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112013017752A8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2824422A1 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1244693A1 (cg-RX-API-DMAC10.html) |
| IL (3) | IL295359A (cg-RX-API-DMAC10.html) |
| MX (3) | MX385629B (cg-RX-API-DMAC10.html) |
| SG (4) | SG191334A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012097019A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| WO2016005381A1 (en) * | 2014-07-10 | 2016-01-14 | Bayer Pharma Aktiengesellschaft | Pdgfrbeta-fc fusion proteins and uses thereof |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN106999511A (zh) * | 2014-12-11 | 2017-08-01 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| AU2016224843B2 (en) * | 2015-02-26 | 2019-12-05 | Feramda Ltd. | Compositions and combinations for the treatment of angiogenesis diseases and disorders |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| WO2017046140A1 (en) * | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| EP3380194B1 (en) | 2015-11-24 | 2023-11-01 | Indiana University Research & Technology Corporation | Composition for blocking angiogenesis |
| KR20210157427A (ko) | 2015-12-03 | 2021-12-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| EP3463349B1 (en) | 2016-05-25 | 2021-08-04 | Santen Pharmaceutical Co., Ltd. | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema |
| CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| EP3573641A4 (en) * | 2017-01-25 | 2020-11-11 | Iconic Therapeutics, Inc. | TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| AU2018370135A1 (en) * | 2017-11-16 | 2020-06-04 | Iveric Bio, Inc. | A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV) |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| KR20200093621A (ko) * | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CN111699004A (zh) | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| MX2020009140A (es) * | 2018-03-16 | 2020-09-28 | Novartis Ag | Metodos para el tratamiento de enfermedades oculares. |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
| CN119033684A (zh) | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2020241660A1 (ja) * | 2019-05-28 | 2020-12-03 | 学校法人順天堂 | 糖尿病網膜症の予防又は治療薬 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020345174A1 (en) * | 2019-09-12 | 2022-03-31 | Lupin Limited | Modified dosing of VEGF inhibitors for ophthalmic use |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| MX2022006751A (es) | 2019-12-06 | 2022-08-19 | Regeneron Pharma | Minitrampas de vegf y metodos de uso de las mismas. |
| KR102426802B1 (ko) * | 2019-12-23 | 2022-07-28 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물 |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| US12692301B2 (en) | 2020-06-11 | 2026-07-28 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
| WO2022186335A1 (ja) * | 2021-03-03 | 2022-09-09 | 学校法人自治医科大学 | 副作用の予測方法およびそのための装置 |
| EP4323399A4 (en) * | 2021-04-14 | 2025-04-09 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| FI4185318T3 (fi) * | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| JP2024526080A (ja) * | 2021-06-23 | 2024-07-17 | サイチューン ファーマ | インターロイキン１５多様体 |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024168252A2 (en) * | 2023-02-10 | 2024-08-15 | Yale University | Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy |
| CN121712520A (zh) * | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| EP4761750A1 (en) * | 2023-08-17 | 2026-06-24 | Innovent Biologics (Suzhou) Co., Ltd. | Methods of treating age-related macular degeneration and diabetic macular edema |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| CN101433715B (zh) * | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| HRP20040406A2 (en) | 2001-11-09 | 2005-02-28 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| JP2003309411A (ja) | 2002-04-17 | 2003-10-31 | Alps Electric Co Ltd | 複合アンテナ |
| US7300563B2 (en) | 2003-02-07 | 2007-11-27 | Pavco, Inc. | Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths |
| JP4730909B2 (ja) | 2003-03-28 | 2011-07-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆ媒介性活性を遮断することにより糖尿病を処置する方法 |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US20040266688A1 (en) | 2003-05-14 | 2004-12-30 | Nayak Nihar R | Methods for modulating endometrium |
| AU2004242586C1 (en) | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US7422741B2 (en) | 2004-03-05 | 2008-09-09 | Vegenics Limited | VEGFR-3 fusion proteins |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| EP2583685A1 (en) | 2004-06-10 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| EP1755645A2 (en) | 2004-06-18 | 2007-02-28 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
| CN1997386B (zh) | 2004-07-30 | 2012-05-30 | 瑞泽恩制药公司 | 通过阻断vegf介导的活性来治疗i型糖尿病的方法 |
| PT1802334E (pt) * | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| EP1877438A2 (en) * | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| AU2006279658A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a VEGF antagonist |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| CA2666709A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| JP6071099B1 (ja) | 2014-01-25 | 2017-02-01 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管の新生又は成長を抑制する融合タンパク質及びその用途 |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
-
2012
- 2012-01-11 KR KR1020187004862A patent/KR20180023015A/ko not_active Ceased
- 2012-01-11 KR KR1020257043583A patent/KR20260004598A/ko active Pending
- 2012-01-11 KR KR1020247022007A patent/KR20240110092A/ko not_active Ceased
- 2012-01-11 KR KR1020217007359A patent/KR20210030510A/ko not_active Ceased
- 2012-01-11 JP JP2013549502A patent/JP2014503555A/ja not_active Withdrawn
- 2012-01-11 MX MX2017010249A patent/MX385629B/es unknown
- 2012-01-11 EP EP17168808.8A patent/EP3222285A1/en not_active Withdrawn
- 2012-01-11 KR KR1020227021482A patent/KR20220097542A/ko not_active Ceased
- 2012-01-11 SG SG2013048798A patent/SG191334A1/en unknown
- 2012-01-11 IL IL295359A patent/IL295359A/en unknown
- 2012-01-11 SG SG10201802789VA patent/SG10201802789VA/en unknown
- 2012-01-11 KR KR1020137018185A patent/KR20140043313A/ko not_active Ceased
- 2012-01-11 KR KR1020197012536A patent/KR20190049934A/ko not_active Ceased
- 2012-01-11 EP EP20186662.1A patent/EP3763379A1/en not_active Withdrawn
- 2012-01-11 BR BR112013017752A patent/BR112013017752A8/pt not_active Application Discontinuation
- 2012-01-11 EP EP24161447.8A patent/EP4360709A3/en active Pending
- 2012-01-11 WO PCT/US2012/020855 patent/WO2012097019A1/en not_active Ceased
- 2012-01-11 SG SG10201509193UA patent/SG10201509193UA/en unknown
- 2012-01-11 SG SG10202111177VA patent/SG10202111177VA/en unknown
- 2012-01-11 MX MX2013007847A patent/MX349901B/es active IP Right Grant
- 2012-01-11 CA CA2824422A patent/CA2824422A1/en active Pending
- 2012-01-11 EP EP12700590.8A patent/EP2663325A1/en not_active Withdrawn
- 2012-01-11 KR KR1020207018126A patent/KR20200077622A/ko not_active Ceased
- 2012-01-11 CN CN201280005207.7A patent/CN103533950A/zh active Pending
- 2012-01-11 AU AU2012205599A patent/AU2012205599B2/en active Active
-
2013
- 2013-06-24 IL IL227160A patent/IL227160B/en active IP Right Grant
- 2013-07-04 MX MX2021006092A patent/MX2021006092A/es unknown
- 2013-07-12 US US13/940,370 patent/US9254338B2/en active Active
-
2015
- 2015-12-17 US US14/972,560 patent/US9669069B2/en active Active
-
2016
- 2016-10-14 JP JP2016202169A patent/JP2017061467A/ja active Pending
-
2017
- 2017-01-17 AU AU2017200290A patent/AU2017200290B2/en active Active
- 2017-03-28 US US15/471,506 patent/US10130681B2/en active Active
-
2018
- 2018-03-27 HK HK18104210.6A patent/HK1244693A1/en unknown
- 2018-06-20 IL IL260167A patent/IL260167A/en unknown
- 2018-08-06 US US16/055,847 patent/US10857205B2/en active Active
- 2018-10-12 US US16/159,282 patent/US10828345B2/en active Active
-
2019
- 2019-04-02 AU AU2019202260A patent/AU2019202260A1/en not_active Abandoned
- 2019-04-29 US US16/397,267 patent/US10888601B2/en active Active
- 2019-06-05 JP JP2019104939A patent/JP2019167366A/ja active Pending
-
2020
- 2020-10-16 US US17/072,417 patent/US11986511B2/en active Active
- 2020-12-04 US US17/112,404 patent/US11730794B2/en active Active
- 2020-12-04 US US17/112,063 patent/US11975045B2/en active Active
-
2021
- 2021-02-12 AU AU2021200935A patent/AU2021200935A1/en not_active Abandoned
- 2021-06-17 US US17/350,958 patent/US11707506B2/en active Active
- 2021-06-21 US US17/352,892 patent/US11253572B2/en active Active
- 2021-09-09 JP JP2021146749A patent/JP2021193115A/ja active Pending
-
2022
- 2022-05-10 US US17/740,744 patent/US11559564B2/en active Active
-
2023
- 2023-10-06 JP JP2023174006A patent/JP7733706B2/ja active Active
- 2023-10-27 US US18/496,472 patent/US12268730B2/en active Active
-
2024
- 2024-07-05 AU AU2024204677A patent/AU2024204677A1/en active Pending
-
2025
- 2025-01-17 US US19/027,212 patent/US20250152669A1/en active Pending
- 2025-08-20 JP JP2025136675A patent/JP2025169389A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| JP6944958B2 (ja) | 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用 | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| KR102266014B1 (ko) | 안질환 예방 또는 치료용 점안 조성물 | |
| JP2022547537A5 (cg-RX-API-DMAC10.html) | ||
| Adams et al. | Aflibercept | |
| WO2012105610A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| JP2024542777A5 (cg-RX-API-DMAC10.html) | ||
| JP2024516003A5 (cg-RX-API-DMAC10.html) | ||
| JP2021138710A5 (cg-RX-API-DMAC10.html) | ||
| CA2364606C (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| CN112770757B (zh) | 一种治疗纤维化疾病的药物组合或药物组合物 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| JPS6322016A (ja) | 免疫刺激剤 | |
| JP7579027B2 (ja) | セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用 | |
| RU2771869C1 (ru) | Способ проведения анестезиологического сопровождения офтальмологических операций | |
| WO2026040961A1 (zh) | pUDK-HGF注射液的用途 | |
| TWI679013B (zh) | 2β,3α,5α-三羥基雄甾-6-酮用於炎症反應的治療 | |
| RU2103008C1 (ru) | Способ стимуляции apud-системы | |
| IOP | AHFS® firstRelease™ | |
| CN112138013A (zh) | I化合物在制备治疗糖尿病及相关病症的药中的用途 | |
| KR20230007245A (ko) | 이미다졸 유도체를 포함하는 안질환의 예방 또는 치료용 조성물 및 이의 용도 |